TAK
Takeda Pharmaceutical Company Limited
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · JP
$21.06
+1.49%Year over year
Reported trailing growth
- Revenue
- +7.2%
- EBITDA
- +19.3%
- EBIT
- +164.0%
- EPS
- +1026.4%
- Free cash flow
- -54.2%
- Operating cash flow
- -30.6%
Forward estimates
Based on analyst estimates
- Revenue
- -0.6%
- EBITDA
- -9.0%
- EPS
- +5.7%
Three-year CAGR
- Revenue
- +5.9%
- EBITDA
- +2.3%
- EBIT
- +5.3%
- Net income
- -13.8%
- EPS
- -14.5%
- Free cash flow
- +22.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026